End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF)

  • Avi Dor
  • Mark V. Pauly
  • Margaret A. Eichleay
  • Philip J. Held
Article

DOI: 10.1007/s10754-007-9024-9

Cite this article as:
Dor, A., Pauly, M.V., Eichleay, M.A. et al. Int J Health Care Finance Econ (2007) 7: 73. doi:10.1007/s10754-007-9024-9

Abstract

End-stage renal disease (ESRD) is a debilitating, costly, and increasingly common condition. Little is known about how different financing approaches affect ESRD outcomes and delivery of care. This paper presents results from a comparative review of 12 countries with alternative models of incentives and benefits, collected under the International Study of Health Care Organization and Financing, a substudy within the Dialysis Outcomes and Practice Patterns Study. Variation in spending per ESRD patient is relatively small, but correlated with overall per capita health care spending. Remaining differences in costs and outcomes do not seem strongly linked to differences in incentives.

Keywords

End-stage renal disease Dialysis Health care financing Incentives Medical costs Reimbursement Transplantation 

JEL Classifications

I10 I11 I12 I18 

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Avi Dor
    • 1
  • Mark V. Pauly
    • 2
  • Margaret A. Eichleay
    • 3
  • Philip J. Held
    • 3
  1. 1.School of Public Health and Health ServicesGeorge Washington UniversityWashingtonUSA
  2. 2.Wharton School of BusinessUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Arbor Research Collaborative for HealthAnn ArborUSA

Personalised recommendations